Open Access

Research and progress on ClC‑2 (Review)

  • Authors:
    • Hongwei Wang
    • Minghui Xu
    • Qingjie Kong
    • Peng Sun
    • Fengyun Yan
    • Wenying Tian
    • Xin Wang
  • View Affiliations

  • Published online on: May 18, 2017     https://doi.org/10.3892/mmr.2017.6600
  • Pages: 11-22
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chloride channel 2 (ClC-2) is one of the nine mammalian members of the ClC family. The present review discusses the molecular properties of ClC‑2, including CLCN2, ClC‑2 promoter and the structural properties of ClC‑2 protein; physiological properties; functional properties, including the regulation of cell volume. The effects of ClC‑2 on the digestive, respiratory, circulatory, nervous and optical systems are also discussed, in addition to the mechanisms involved in the regulation of ClC‑2. The review then discusses the diseases associated with ClC‑2, including degeneration of the retina, Sjögren's syndrome, age‑related cataracts, degeneration of the testes, azoospermia, lung cancer, constipation, repair of impaired intestinal mucosa barrier, leukemia, cystic fibrosis, leukoencephalopathy, epilepsy and diabetes mellitus. It was concluded that future investigations of ClC‑2 are likely to be focused on developing specific drugs, activators and inhibitors regulating the expression of ClC‑2 to treat diseases associated with ClC‑2. The determination of CLCN2 is required to prevent and treat several diseases associated with ClC‑2.

Introduction

Chloride channels (ClCs) are a type of permeable channel protein for chloride ions or other anions on the cell membrane, and ClC proteins are encoded by genes of the ClC family. ClCs have nine family members, which are classified into three distinct subfamilies: ClC-1, ClC-2, ClC-Ka/K1 and ClC-Kb/K2; ClC-3, ClC-4 and ClC-5; and ClC-6 and ClC-7 (1). ClC-2 is one of the nine mammalian members of the ClC family, and was initially isolated from the rat heart and brain (2,3) and then from the rabbit heart (4,5). ClC-2 is a two-pore homodimeric, voltage-gated Cl channel (58). ClC-2 can be activated by hyperpolarization (3,9), cell swelling (2,9), extracelluar hypotonicity (2) and extracellular acidification (9,10). ClC-2 is almost ubiquitously expressed (3,11), including in ureteric bud cells (12), intestine (1317), gastric parietal cells (18,19), the liver (20), lung (11,2126), rat retina (27), parotid acinar cells (28), guinea pig cardiac muscle (29), neuronal cells (30), rat and human airways (17), bovine trabecular meshwork (31), human trabecular meshwork (32,33) and rat trabecular meshwork (34). In addition, ClC-2 can regulate cell volume (2,4,35), control response to swelling (11,3639), and regulates post-synaptic responses to GABA and glycine (11,40,41).

Although ClC-2 has a wide variety of properties and functions, repots of CLC-3 prior to 1994 are limited, with only six published between 1953 and 1994. Between 1994 and 2015, ClC-2 attracted increasing attention as ClC-2 was understood to possess several molecular, functional and physiological properties, and be associated with several diseases, including degeneration of the retina, Sjögren's syndrome, age-related cataracts, degeneration of the testes, azoospermia, lung cancer, constipation, repair of impaired intestinal mucosa barrier, leukemia, cystic fibrosis, leukoencephalopathy, epilepsy and diabetes mellitus. However, reviews on ClC-2 are limited. The present review aimed to discuss the molecular, functional and physiological properties of ClC-2, in addition to mechanisms involved in the regulation of ClC-2 and diseases associated with ClC-2.

Molecular properties of ClC-2

CLCN2 and ClC-2 promoter

The ClC-2 protein is encoded by the CLCN2 gene, which is composed of 898 amino acids and is located in chromosome 3q27.1. The major transcription start site of the ClC-2 gene has been identified, and is localized 100 bp upstream of the putative translation initiation codon (21). A previous study (42) on the possible evolution of ClC-2 gene suggested that ClC-2 may have evolved by gene duplication, mutation and DNA rearrangement (27,43).

The ClC-2 promoter belongs to a GC-rich and TATA-less class (44). Within the 1,930-bp region, one of three CAAT boxes is close to the ClC-2 coding sequence, and the other two are at the middle (44). Within a 391-bp region upstream, the first three of four GC boxes are conserved in human ClC-2, as reported by Cid et al (21,44).

Structural properties of ClC-2 protein

Despite wide functional diversity, ClC family members share a conserved protein structure, including a transmembrane region, which is involved in chloride anion transport, and two intracellular copies of the cystathionine-β-synthase (CBS) domain (CBS1 and CBS2) (58,45,46) and an N-terminus. Therefore, the protein structure of ClC-2 is the same in the other ClC family members (45,46), as shown in Fig. 1.

Several other studies on the structural properties of ClC-2 have reported that the ClC-2 dimer is the minimum functional structure (47), protons act independently from the possible effects of the N-terminus on gating (48) and the hetero-dimerization of ClC-2 can modify the unitary conductance of protopores (49).

Biophysical properties of ClC-2

In 1992, it was reported that ClC-2 expressed in Xenopus oocytes generates Cl currents, which activate slowly upon hyperpolarization and show a linear instantaneous current-voltage association (3). Further studies on the biophysical properties on ClC-2 have focused predominantly on Cl currents, including ClC-2-like inwardly rectifying Cl currents (3,5054) and ClC-2 outwardly rectifying Cl currents (36,37,52,5559).

ClC-2-like inwardly rectifying Cl currents have been detected in the human T84 cell line (50), drosophila ClC-2 variants in HEK-293 cells (51) and rat type IV spiral ligament fibrocytes (52). The conductivity sequence of the inwardly rectifying currents is Cl ≥ Br > I (3). ClC-2 inwardly rectifying Cl currents are inhibited by 4,4′-diisothiocyano-2,2′-stilbenedisulfonic acid (DIDS) (3) and Cd2+ (50), and regulated by cell swelling (53), extracellular pH, Cl and Ca2+ (52). However, the results of another study on ClC-2 inwardly rectifying Clcurrents differed, reporting that ClC-2 did not significantly contribute to inward-rectifying anion conductance in the mouse choroid plexus (54).

ClC-2 outwardly rectifying Cl currents have been found in the T84 human adenocarcinoma cell line (36,37,55), human neurons (56), human parotid acinar cells (57) and rat type IV spiral ligament fibrocytes (52). The outwardly rectifying currents are characterized by a time-dependent decay at depolarizing voltages, and the anion permeability sequence I>Br >Cl>F, and the currents show sensitivity to 1,9-dideoxyforskolin, DIDS (58) and tamoxifen (55). ClC-2 outwardly rectifying Cl currents are regulated by extracellular pH, Cl and Ca2+ (52). Another study showed that ClC-2 may contribute to cell volume regulation following hyposmotic stress produced by outwardly rectifying Clcurrents, however, cell volume regulation in T84 cells is independent of ClC-2 activity (59).

ClC-2 inwardly/outwardly rectifying Cl currents are simultaneously found in rat type IV spiral ligament fibrocytes (52), and they are modulated by extracellular pH, Cl and Ca2+. According to previous studies, at least two chloride channels are involved in modulating membrane anion conductance (52). Another study on Cl currents in rabbit heart cells suggested that rabClC-2α/2β may provide two homologous protein kinase A-activated chloride anion channels, with or without extracellular hypotonicity (60).

Functional properties of ClC-2

Previous studies have shown that ClC-2 has several functional properties, including effects on cell volume (2,4,20,35,61), the digestive system (11,16,18,19,6264), the eye (6567), respiratory system (11,24,26,6870), circulatory system (35,7175) and nervous system (76). In addition, several studies have reported the functions of the NH2 terminus (77) and carboxy terminus (78) in ClC-2, and the similar functional properties between chloride-selective ion channels, including ClC-2, in protozoa (7982).

Regulation of cell volume

The activation of ClC-2 in response to cell swelling and low extracellular pH is involved in the dissociation of an NH2-terminal region of ClC-2 (10). The dephosphorylation of serine/threonine residues in the channel or an associated protein appears to be necessary for current activation following cell swelling in T84 cells (53) and for a ClC-2-like current in ascidian embryo cells during the cell cycle (83). Hypotonic cell swelling activates an outwardly rectifying anionic conductance, with different characteristics from those of ClC-2 previously reported (84). The endogenous currents suggest that protein tyrosine phosphorylation is involved in the signal transduction pathway in certain cell types (8587), and that epidermal growth factor enhances the hypotonicity-induced anionic efflux (85). However, tyrosine kinase p56lck activates these swelling-sensitive chloride channels without cell swelling, even during cell shrinkage, in lymphocytes (88).

Effect of ClC-2 on the digestive system

Nehrke et al (62) detected the regulatory volume decrease following cell swelling, which showed that ClC-2 can control cell volume in mouse parotid acinar cells. Others functions of ClC-2 have been reported, including HCl secretion across the parietal cell secretory membrane in the rabbit gastric mucosa (19), mediating the basolateral membrane exit of Cl in the distal colon of guinea pigs (16), regulating gastric acid secretion (11,18,63), and affecting gastric glands and its cell layers (63). However, one study suggested that ClC-2 may not be a Cl-transporting protein for gastric acid secretion in parietal cells (64).

Effect of ClC-2 on the eye

Previous studies have shown that CIC-2 has a protective effect on trabecular cells under pressure stress (65), can regulate the inward rectification in Drosophila retinal photoreceptors (66), and can modulate cellular volume, intracellular Cl and other cellular functions in trabecular meshwork cells (67).

Effect of ClC-2 on the respiratory, circulatory and nervous systems

ClC-2 is gestationally regulated and is predominantly expressed in the fetal lung (26,68). Cystic fibrosis transmembrane conductance regulator (CFTR)-independent fluid accumulation is induced by keratinocyte growth factor in fetal lung explants (69), and keratinocyte growth factor is necessary for ClC-2-like pH-sensitive Cl secretion in the fetal airway epithelia (24). It has been shown that ClC-2 affects fetal lung fluid production and lung cyst morphology (70).

It has been reported that a novel Cl inward rectifier channel is found in the cardiac atrial and ventricular myocytes of several species, including the guinea pig (7173), mouse (71,73) and rat (7275). The Cl inward rectifier channels have properties of activation by hypotonic cell swelling and extracellular acidification, inward rectification, time-dependent slow activation and Cd2+-sensitive inhibition (7175). Experiments have shown that ClC-2 affects the positive chronotropic effect of acute exercise stress (73) and modulates cardiac pacemaker activity (73), but cannot alter intrinsic heart rate (73).

Another study (76) investigating the effect of ClC-2 on inhibitory interneurons showed that membrane voltage-/intracellular chloride-dependent ClC-2 can selectively regulate GABAA receptor (GABAA R)-mediated synaptic inputs from basket cells.

Mechanisms of ClC-2 regulation by regulators

Cell swelling can increase ClC-2 activity (2,9), and ClC-2 can be activated by hyperpolarization (3,9), extracelluar hypotonicity (2) and extracellular acidification (9,10). Previous studies have shown that ClC-2 is also regulated by hormones (8991), drugs (92100), proteins (101107), kinases (108114), transcription factors (115,116), inhibitors (117120), scorpion venom (121), α1-adrenoceptor (122), Plasmodium berghei (123), adenosine triphosphate (124,125), ClH3 (40,126137), permeant anions (138,139), membrane cholesterol (140) and the tyrosine endocytosis motif (141).

Regulation of ClC-2 by hormones

Thyroid hormones (T3 and T4) can regulate renal function (142,143), Na+/K+ ATPase (144), Na+/H+ exchanger (145), and affect kidney growth and development (146). Previous studies have demonstrated that hyperthyroidism and hypothyroidism are associated with chloride (147,148), and the reversal of glomerular filtration by T4 is observed in patients with hypothyroidism (149). In addition, a previous study (89) on T4 suggested that ClC-2 is involved in chloride transport regulated by thyroid hormones in rat renal proximal tubules.

Estrogen is associated with a decrease in the urinary excretion of sodium and chloride (150153). A study by Nascimento et al (90) showed that ClC-2 may be involved in estrogen-induced Cl transport in the rat kidney. Another study (91) showed that ClC-2 is also involved in the rat renal tubule transcellular chloride transport regulated by arginine vasopressin, a neurohypophysial hormone.

Regulation of ClC-2 by drugs

Lubiprostone can induce intestinal fluid secretion (154), treat constipation (155157) and activate ClC-2 Cl currents in a concentration-dependent manner (94), and ClC-2 can recover mucosal barrier function in the ischemia-injured intestine (92). Studies have shown that the activation of ClC-2 by lubiprostone can stimulate the recovery of intestinal barrier function in the ischemia-injured porcine ileum and colon (93), and may have a protective and therapeutic effect on murine models of colitis (99). The prostaglandin E2 receptor 4 [EP (4)] receptor (9497) can stimulate ClC-2 and CFTR chloride channels, and it has been shown (98) that lubiprostone can activate CFTR by the EP (4) receptor in oocytes. The Chinese medicinal compounds Guanxinkang and diltiazem hydrochloride can decrease the mRNA and protein expression of ClC-2 in rats with myocardial ischemia reperfusion injury (100).

Regulation of ClC-2 by proteins

The functional expression and activation of ClC-2 is reduced by dynein (a protein complex) (101) and p34cdc2/cyclin B (102), however, the inrerferon-γ glycoprotein can activate ClC-2 in lung epithelial cells through mRNA stabilization, and increase ClC-2 transcripts in Calu-3 cells (107). ClC-2 is regulated by protein phosphatase 1 (102), interactions between the actin cytoskeleton (a filamentous protein structure) and the N-terminus of ClC-2 (104). M phase-specific p34cdc2/cyclin B can phosphorylate the ubiquitination of ClC-2 (103). Heat shock protein 90 can increase ClC-2 current amplitude and the intracellular Cl concentration, and enhance channel sensitivity to intracellular Cl (105). ClC-2 is also associated with the transmembrane glycoprotein, GlialCAM, in the brain, and GlialCAM can involve ClC-2 in the homeostasis of myelin, which is defective in leukodystrophy (106).

Regulation of ClC-2 by kinases

ClC-2 membrane abundance is increased by serum and glucocorticoid inducible kinases (SGKs) and decreased by NEDD4-2, an enzyme of the NEDD4 family (108). In rats, protein kinase A can directly phosphorylate ClC-2, whereas protein kinase C and Ca2+/calmodulin-dependent protein kinase II cannot (113). PIKfyve is a FYVE finger-containing phosphoinositide kinase (158) and is a potent stimulator of ClC-2-activity (112), which can contribute to the SGK1-dependent regulation of ClC-2 (112).

Janus kinase (JAK) 2 and JAK3 (tyrosine kinase) can downregulate the activation of ClC-2 and offset Cl exit (109,111), however, their functions and regulatory mechanism are different. JAK2 is involved in the signaling of leptin (159), growth hormones (160), erythropoietin, thrombopoietin, granulocyte colony-stimulating factor (161) and a variety of cytokines (161,162). JAK2 inhibitors can treat myeloproliferative disorders (163170), and JAK2 can be activated by hyperosmotic shock (171,172). By contrast, JAK3 can promote proliferation and act against the apoptosis of lymphocytes and tumor cells (173177). It is also present in acute megakaryoplastic leukemia (178,179). Therefore, cell proliferation and apoptosis is associated with Cl channel activity (110). In addition, the substitution of lysine by alanine can inactivate JAK3 (180). In addition to JAK2 and JAK3, SPS1-related proline/alanine-rich kinase and oxidative stress-responsive kinase 1 can also downregulate ClC-2 (114).

Regulation of ClC-2 by transcription factors

The Sp1 and Sp3 transcription factors can control the rate of transcription of genetic information from DNA to messenger RNA (181,182). Reducing interactions between Sp1 or Sp3 and the ClC-2 promoter can lead to a postnatal decrease in the expression of ClC-2 in lung epithelia (116). In addition, the glycosylation of SP1 produces the 105-kD isoform of SP1 and is involved in regulating the expression of ClC-2 (115).

Regulation of ClC-2 by inhibitors

Previous studies have shown that ClC-2 is inhibited by methadone (117), gating modifier of anion channels 2 (GaTx2) (118), DIDS (119) and 5-nitro-2-(3-phenylpropylamino) benzoic acid (NPPB) (120). However, DASU-02, as an inhibitor of common chloride channels, cannot inhibit ClC-2 (117). The inhibitory effects on ClC-2 by these inhibitors are entirely different. Methadone can inhibit the activities of ClC-2, which shows that ClC-2 may be involved in chloride anion secretion (117). GaTx2, as a peptide toxin inhibitor of ClC-2, can inhibit channel activation gating, but not other chloride channels or voltage-gated potassium channels (118). DIDS can significantly reduce the increased mRNA and protein levels of ClC-2 following ischemia-hypoxia damage (119). NPPB, as a ClC inhibitor, can affect the phagocytosis of human trabecular meshwork cells, which shows that ClC-2 may be involved in the regulation of its phagocytic process (120).

Other factors in the functional regulation of ClC-2

According to previous studies, in addition to the above-mentioned regulatory mechanisms, scorpion venom (121), α1-adrenoceptor (122), Plasmodium berghei (123), adenosine triphosphate (124,125), ClH3 (137), GABAAR (40,126128), permeant anions (138,139), membrane cholesterol (140) and β-cyclodextrin sensitive clusters (141) can also regulate or affect ClC-2. A peptide of scorpion venom can induce slower activation kinetics of ClC-2 (121). α1-adrenoceptor activation can significantly reduce protein levels of ClC-2 in the villus and crypt epithelial cells from the acutely denervated jejunum, but not the innervated jejunum (122). The activation of ClC-2 is involved in the altered permeability caused by Plasmodium berghei infection in Plasmodium berghei-infected mouse CLCN2 (123). ATP not only decelerates ClC-2 common gating for sufficient electrical stability of neurons (124), it also alters its surface expression (125). Intra-/extra-cellular permeant anions can affect the Vm-dependence of ClC-2 (138). Specially, Cl as a permeant anion can increase pore occupancy, thus obstructing the closure of the protopore gate of ClC-2 (139). In addition, alterations in the (Cl)i between 10 and 200 mM can decelerate ClC-2 channel closing at a positive Vm (139). Membrane cholesterol can regulate the activation of ClC-2, and the increased activation of ClC-2 is involved in the relocalization of ClC-2 to detergent-soluble microdomains (140). β-cyclodextrin sensitive clusters with other molecules can mantain ClC-2 activity (141).

Previous studies have reported that ClH3 encodes the Caenorhabditis elegans homologs of ClC-2 (129131). ClH3-dependent regulation not only alters the voltage dependence of ClC-2 channels and inhibits hereditary sensory neuropathy (HSN) excitability (137), but may also affect chloride influx (137) in Caenorhabditis elegans. However, the chloride efflux pathway of ClC-2 is associated with synaptic inhibition regulated by the GABAAR (40,126128). In addition, the HSNs can release acetylcholine, serotonin and multiple neuropeptides (133136), which excite the VC motor neurons (132). These functions of HSNs may be associated with clh-3-dependent regulation and the voltage dependence of ClC-2 channels.

Diseases associated with ClC-2

Previous studies have shown that disruption and abnormity of ClC-2 can cause a number of diseases, including ophthalmological disease (11,183185), otorhinolaryngological disease (186), disease of the reproductive system (11,187), disease of the respiratory system (188), disease of the digestive system (189194), disease of the hematological system (195), genetic diseases (23,25,26,42,44,74,76,196198), diseases of the nervous system (30,40,41,168,199212) and metabolic diseases (213). The majority of studies have focused on diseases of the nervous system.

Ophthalmological and otorhinolaryngological disease associated with ClC-2

Severe degeneration of the retina occurs in ClC-2-knockout mice, although no other notable eye abnormalities are present (11). Possible reasons for degeneration of the retina caused by ClC-2-knockout include the following (11): i) ClC-2 disruption causes the death of photoreceptor cells; ii) depletion of ClC-2 may impair the transport and alter the ionic environment of photoreceptors. Other studies on ophthalmological diseases associated with ClC-2 include Sjögren's syndrome (183,184,214218) and age-related cataracts (185).

Sjögren's syndrome is a chronic autoimmune disease, and previous studies have shown that eye diseases caused by Sjögren's syndrome are primarily through the destruction of lacrimal glands (LGs) (214), keratoconjunctivitis sicca (215). In addition, LG pathologic properties in Sjögren's syndrome appear in rabbits induced by autoimmune dacryoadenitis (216218). Acini and interlobar ducts have the lowest mRNA abundance of ClC2γ, and the intralobar duct has the highest (183,184), and alterations in ClC2γ may alter lacrimal secretion, particularly Cl transport (184). The causes of age-related cataracts include aging, inheritance, local nutritional disorders, immune and metabolic abnormalities, trauma, poisoning and radiation. According to a study by Ouyang (185), the expression level of ClC-2 is associated with the development of age-related cataracts.

Reports on otorhinolaryngological diseases associated with ClC-2 are limited, however, Li et al reported on the pathogenesis of nasal polyps. The study (186) showed that ClC-2 was not expressed in normal nasal mucosa, however, ClC-2 proteins were expressed in epithelial cells and sub-epithelial mucous glands in patients affected with nasal polyps. This suggested that ClC-2 is involved in the pathogenesis of nasal polyps.

Diseases of the reproductive system associated with ClC-2

In previous studies, a number of diseases of the reproductive system have been associated with ClC-2, including degeneration of the testes (11) and azoospermia (187,219,220).

It was shown that severe degeneration of the testes appears in ClC-2-knockout mice, however, no other reproductive abnormalities are observed (11). A study by Bösl et al suggested that ClC-2 disruption causes the death of germ cells, impaired transport and alterations to the ionic environment of germ cells, and that germ cells rely on the transepithelial transport mediated by Sertoli cells (11).

Azoospermia is a medical condition in which males do not have a measurable level of sperm in their semen, and is associated with low levels of fertility or infertility. Its pathogenesis involves CFTR disruption in CF, affecting male fertility (219). In addition, the male sterility resulting from reduced fluid volume is associated with disruption of Cl channels from other ClCN genes (220). Another study (187) by Edwards et al reported that ClCN2nmf240 homozygotes have azoospermic symptoms severe degradation of spermatogenesis, and shortages of spermatocytes, spermoblasts and sperm.

Diseases of the respiratory system associated with ClC-2

Reports on diseases of the respiratory system associated with ClC-2 are limited. A previous study (188) reported that ClC-2 may be important in the invasion, development and occurrence of lung cancer, and that ClC-2 may be a novel molecular target for clinical therapy in non-small cell lung cancer.

Diseases of the digestive system associated with ClC-2

There have been several reports on diseases of digestive system associated with ClC-2, including constipation (18,26,189193,221) and repair of impaired intestinal mucosa barrier (194).

CFTR is major chloride channel regulating chloride secretion in the small intestine (221), however, ClC-2 can also regulate chloride secretion (18,26). Hypotonicity can also activate chloride currents in the rat ileum (189). Several studies have reported that ClC-2 is expressed in the intestinal epithelium, in T84 human intestinal cells, rat intestinal tissue (3) and the murine duodenum (190). In addition, previous studies have shown that ClC-2 can regulate chloride secretion in rodent neonatal airways (26), and regulate gastric chloride secretion (18). However, another study (191) described contradictory findings, reporting that ClC-2 was not involved in Cl secretion, but was involved in Cl absorption in the distal colon. According to these studies, ClC-2 inhibitors may be used to treat constipation by decreasing NaCl and water absorption in the colon (191).

Irritable bowel syndrome (IBS) is characterized by chronic abdominal pain, discomfort and bloating associated with altered bowel habits, including diarrhea and/or constipation. Current therapy for constipation caused by IBS has side effects, including deterioration of the condition or electrolyte disturbances (192). Previous studies have shown that, in addition to the above-mentioned side effects, lubiprostone can also increase gut motility and frequency of stool passage, relieve abdominal pain and discomfort (192), stimulate chloride secretion and improve bowel function (193).

A previous study (194) by Chen et al reported that the activation of ClC-2 can activate tight junction proteins and repair impaired intestinal mucosa barrier. In addition, ClC-2 and tight junction proteins are involved in maintenance of the intestinal mucosal barrier, and acute biliary obstruction-induced destruction of the intestinal mucosa barrier is associated with ClC-2 in enterocytes (194).

Diseases of the hematological system associated with ClC-2

There have been few studies on diseases of the hematological system associated with ClC-2. A previous study reported the expression of swelling-and/or pH-regulated ClC-2 chloride channels in human leukemia (195). In addition, it was suggested that the molecular identification of chloride channels may provide a novel approach for the treatment of leukemia (195).

Genetic diseases associated with ClC-2

According to previous reports, there have been several studies on the association between CF and ClC-2 (3,11,23,25,26,68,70,196198,222,223). Several studies have reported that ClC-2 may be an alternative pathway for chloride anion secretion in CF (3,11,23), and that ClC-2 is a potential target for therapy in CF (25,197). CF is a genetic disease, which primarily affects the lungs, in addition to the pancreas, liver, kidneys and intestine (222). CF is caused by mutations in the gene encoding CFTR, the only member of the ABC transporter family known to be a cAMP-activated chloride channel (223). ClC-2 is a candidate alternative chloride channel in respiratory epithelia (196). ClC-2 is also involved in lung morphogenesis (26,68), and can conduct chloride in mature respiratory epithelia (23,25,197). ClC-2 mRNA and protein are expressed in unaffected tissues in CF, which may make up for defects in the expression of CFTR (68).

However, another previous study (198) reported that ClC-2 is unlikely to be a candidate rescue channel in CF, as disruption of ClC-2 and CFTR channel genes did not cause morphological alterations in the intestine, lung or pancreas affected by CF; neither disrupted ClC-2 or CFTR reduced Cl secretion (198). In addition, two studies (70,196) refer to the importance of detecting modifications of CF by ClC-2, and underlined the importance of examining potential polymorphisms in subjects affected with CF and potential mutations in the coding region of ClC-2.

Diseases of the nervous system associated with ClC-2

There have been more studies on diseases of the nervous system associated with ClC-2, compared with other diseases associated with ClC-2. Studies on diseases of the nervous system associated with ClC-2 have predominantly focused on leukoencephalopathy (199202,224) and epilepsy (30,40,203212,225).

Leukoencephalopathy can refer specifically to any of the following diseases: Progressive multifocal leukoencephalopathy, toxic leukoencephalopathy, leukoencephalopathy with vanishing white matter, leukoencephalopathy with neuroaxonal spheroids, reversible posterior leukoencephalopathy syndrome, megalencephalic leukoencephalopathy with subcortical cysts (MLC) and hypertensive leukoencephalopathy. Among these, MLC is a rare type of leukodystrophy, which is characterized by macrocephaly emerging in the first years of life (224).

The disruption of ClC-2 can cause fluid accumulation resulting in myelin vacuolation in mice, similar to that observed in humans affected with MLC from mutations in MLC1 or GlialCAM. GlialCAM is a ClC-2 binding partner and the first auxiliary subunit of ClC-2 (199). According to a study by Jeworutzki et al (199), neither the stimulation of GlialCAM on ClC-2 currents, nor mislocalization of this Cl channel were found to damage glial Cl transport. Mutated GlialCAM in MLC can target ClC-2 to cell contacts in glia and activate its currents (200). A study by Jeworutzki et al (200) showed that GlialCAM can target the common gate deficient ClC-2 mutant, E211V/H816A, to cell contacts without altering its function. Another study suggested that ClC-2 is not important for MLC1 or GlialCAM localization in the brain (201), but that it is involved in the pathogenesis of MLC (201).

However, a separate study (202) reported different conclusions, as there was no evidence that the CLCN2 gene is associated with MLC. Despite not referring to the association between the CLCN2 gene and MLC, this study demonstrated that mice lacking the ClC-2 protein had white matter abnormalities with vacuole formation in myelin sheaths, similar to the intramyelinic vacuoles in MLC.

Epilepsy comprises a set of neurological diseases characterized by epileptic seizures, and a heterogeneous disorder characterized by recurrent unprovoked seizures, which affect ~1–3% of the population during their lifetimes (225). ClC-2 mRNA and protein are found in neurons and astrocytes (30,40,203). In addition, ClC-2 protein is present at the end feet of astrocytes contacting blood vessels and neurons close to inhibitory synapses (30). Inwardly rectifying hyperpolarization-activated ClC-2-like currents are found in hippocampal pyramidal cells (40,127) and in astrocytes (204207). In hippocampal pyramidal cells and astrocytes (208), ClC-2 may have different effects. In neurons, ClC-2 can prevent the accumulation of chloride anions above equilibrium due to the activation of ClC-2 by intracellular Cl (41,127). Under these conditions, GABAA R activity may become excitatory (208). A previous study (208) reported that loss of function mutations of ClC-2 lead to increased excitability in certain neurons, and that hyperpolarization-activated chloride currents are detected in cortical astrocytes, but absent in tissues from ClC-2-null mice (207). Another study (211) showed that several ClC-2 sequence abnormalities previously found in patients affected with epilepsy are likely to represent innocuous polymorphisms, detected by sequencing of a large collection of human DNA and electrophysiological analysis.

Several other studies have reported that a susceptibility locus for idiopathic generalized epilepsy (IGE) is on chromosome 3q26 (the location of the CLCN2 gene) (209), and three mutations on ClC-2 cosegregated with IGE with autosomal dominant inheritance (210) have been identified.

In addition to the above-mentioned studies on the association between epilepsy and ClC-2, an association between temporal lobe epilepsy (TLE) and ClC-2 has been reported. TLE with spontaneous recurrent attacks, and learning and memory disabilities, is associated with neurodegeneration, abnormal reorganization of the circuitry and loss of functional suppression in hippocampus (212). A study by Ge et al reported that ClC-2 contributes towards tonic inhibition, modulated by α5 subunit-containing GABAA Rs in the CA1 area (212).

Metabolic diseases associated with ClC-2

Few studies on metabolic diseases associated with ClC-2 have been performed, however, a study on diabetes mellitus was found. Diabetes mellitus is a metabolic disease, which generally causes chronic delayed wound healing. In a study by Pan et al (213), a high glucose concentration inhibited keratinocyte migration by downregulating ClC-2, suggesting ClC-2 may be important during delayed wound healing processes. In addition, the study reported that ClC-2 is an important modulator of cell migration in keratinocytes, although it did not discuss how ClC-2 is involved in keratinocyte migration.

Conclusion

With the continuous progress in experimental and clinical studies on the ClC family, it is clear that the activation of ClC-2 occurs via hyperpolarization (3,9), cell swelling (2,9), extracelluar hypotonicity (2) and extracellular acidification (9,10), and that the expression of ClC-2 is ubiquitous (3,11) in ureteric bud cells (12), the intestine (1317), gastric parietal cells (18,19), the liver (20), the lungs (2125), rat retina (27), parotid acinar cells (28), guinea pig cardiac muscle (29), neuronal cells (30), rat and human airways (17), bovine trabecular meshwork (31), human trabecular meshwork (32,33) and rat trabecular meshwork (34). Although there has been progress in understanding the CLCN2 gene, the molecular structure of the ClC-2 protein, the structure of ClC-2 chloride channels, and the functional properties and mechanisms regulating ClC-2, they remain to be fully elucidated and there have been contradictions in previous studies (226). According to previous studies, it is known that the disruption of ClC-2 can lead to several diseases. Although ClC-2 is associated with the pathogenesis of several diseases, the association between pathogenesis and ClC-2 remains to be fully elucidated.

At present, >6,500 types of genetic disease have been identified, among which ~3,000 are caused by a single gene defect. In this review, the mechanisms underlying the association between the CLCN2 gene and diseases, including azoospermia and IGE, were discussed. In the future, investigations focused on the determination of the CLCN2 gene may identify novel methods to treat and prevent several diseases associated with ClC-2. In addition, as the overexpression and underexpression of ClC-2 can cause diseases, the development of specific ClC-2 activators and inhibitors, and understanding the mechanism of action between the functional properties of ClC-2 and these activators and inhibitors, is required in future investigations to regulate the expression of ClC-2.

As described above, ClC-2 can be regulated by hormones, drugs and scorpion venom. Certain hormones in humans are produced in small quantities, however, they have a substantial effect on health, with underproduction or overproduction leading to a variety of diseases. In addition, scorpion venom can be used to treat cancer and lower blood pressure, and is applied for hemostasis, anticoagulation, as an analgesic and a nerve growth factor. Therefore, future investigations focused on the regulatory mechanisms of hormones, drugs and scorpion venom may assist in developing specific drugs for treating diseases associated with ClC-2.

In conclusion, ClC-2 is important in several diseases and, in order to fully elucidate the structure and function of ClC-2, and the mechanisms regulating ClC-2 associated with disease treatment, examining the associations between ClC-2 and regulators, including hormones, proteins, kinases, transcription factors, scorpion venom, adenosine triphosphate, clh-3, permeant anions, membrane cholesterol, tyrosine endocytosis motif and α1-adrenoceptor is required to develop novel treatment strategies. Therefore, further investigations are required in the future.

Acknowledgements

The study was supported by the Library of Qiqihar Medical University (grant no. 16TQB04; Qiqihar, China).

Glossary

Abbreviations

Abbreviations:

ClCs

chloride channels

IGE

idiopathic generalized epilepsy

MLC

megalencephalic leukoencephalopathy with subcortical cysts

TLE

temporal lobe epilepsy

IBS

irritable bowel syndrome

CF

cystic fibrosis

LG

lacrimal glands

DIDS

4,4′-diisothiocyano-2,2′-stilbenedisulfonic acid

CFTR

cystic fibrosis transmembrane conductance regulator

HSN

hereditary sensory neuropathy

JAK2

janus kinase 2

JAK3

janus kinase 3

NEDD4-2

neural precursor cell expressed developmentally downregulated gene 4-like

SGKs

serine/threonine protein kinases

PIKfyve

FYVE finger-containing phosphoinositide kinase

GABAAR

GABAA receptor

EP (4)

prostaglandin E2 receptor 4

References

1 

Strange K: Of mice and worms: Novel insights into ClC-2 anion channel physiology. News Physiol Sci. 17:11–16. 2002.PubMed/NCBI

2 

Gründer S, Thiemann A, Pusch M and Jentsch TJ: Regions involved in the opening of ClC-2 chloride channel by voltage and cell volume. Nature. 360:759–762. 1992. View Article : Google Scholar : PubMed/NCBI

3 

Thiemann A, Gründer S, Pusch M and Jentsch TJ: A chloride channel widely expressed in epithelial and non-epithelial cells. Nature. 356:57–60. 1992. View Article : Google Scholar : PubMed/NCBI

4 

Furukawa T, Ogura T, Katayama Y and Hiraoka M: Characteristics of rabbit ClC-2 current expressed in Xenopus oocytes and its contribution to volume regulation. Am J Physiol. 274:C500–C512. 1998.PubMed/NCBI

5 

Bi MM, Hong S, Zhou HY, Wang HW, Wang LN and Zheng YJ: Chloride channelopathies of ClC-2. Int J Mol Sci. 15:218–249. 2013. View Article : Google Scholar : PubMed/NCBI

6 

Middleton RE, Pheasant DJ and Miller C: Homodimeric architecture of a ClC-type chloride ion channel. Nature. 383:337–340. 1996. View Article : Google Scholar : PubMed/NCBI

7 

Hsiao SH, Parrish AR, Nahm SS, Abbott LC, McCool BA and Frye GD: Effects of early postnatal ethanol intubation on GABAergic synaptic proteins. Brain Res Dev Brain Res. 138:177–185. 2002. View Article : Google Scholar : PubMed/NCBI

8 

Zúñiga L, Niemeyer MI, Varela D, Catalán M, Cid LP and Sepulveda FV: The voltage-dependent ClC-2 chloride channel has a dual gating mechanism. J Physiol. 555:671–682. 2004. View Article : Google Scholar : PubMed/NCBI

9 

Jentsch TJ, Stein V, Weinreich F and Zdebik AA: Molecular structure and physiological function of chloride channels. Physiol Rev. 82:503–568. 2002. View Article : Google Scholar : PubMed/NCBI

10 

Jordt SE and Jentsch TJ: Molecular dissection of gating in the ClC-2 chloride channel. EMBO J. 16:1582–1592. 1997. View Article : Google Scholar : PubMed/NCBI

11 

Bösl MR, Stein V, Hübner C, Zdebik AA, Jordt SE, Mukhophadhyay AK, Davidoff MS, Holstein AF and Jentsch TJ: Male germ cells and photoreceptors, both depending on close cell-cell interactions, degenerate upon ClC-2 Cl(−) channel disruption. EMBO J. 20:1289–1299. 2001. View Article : Google Scholar : PubMed/NCBI

12 

Huber S, Braun G, Schröppel B and Horster M: Chloride channels ClC-2 and ICln mRNA expression differs in renal epithelial ontogeny. Kidney Int Suppl. 67:S149–S151. 1998. View Article : Google Scholar : PubMed/NCBI

13 

Gyömörey K, Yeger H, Ackerley C, Garami E and Bear CE: Expression of the chloride channel ClC-2 in the murine small intestine epithelium. Am J Physiol Cell Physiol. 279:C1787–C1794. 2000.PubMed/NCBI

14 

Bali M, Lipecka J, Edelman A and Fritsch J: Regulation of ClC-2 chloride channels in T84 cells by TGF-alpha. Am J Physiol Cell Physiol. 280:C1588–C1598. 2001.PubMed/NCBI

15 

Mohammad-Panah R, Gyomorey K, Rommens J, Choudhury M, Li C, Wang Y and Bear CE: ClC-2 contributes to native chloride secretion by a human intestinal cell line, Caco-2. J Biol Chem. 276:8306–8313. 2001. View Article : Google Scholar : PubMed/NCBI

16 

Catalán M, Cornejo I, Figueroa CD, Niemeyer MI, Sepúlveda FV and Cid LP: ClC-2 in guinea pig colon: mRNA. immunolabeling, and functional evidence for surface epithelium localization. Am J Physiol Gastrointest Liver Physiol. 283:G1004–G1013. 2002. View Article : Google Scholar : PubMed/NCBI

17 

Lipecka J, Bali M, Thomas A, Fanen P, Edelman A and Fritsch J: Distribution of ClC-2 chloride channel in rat and human epithelial tissues. Am J Physiol Cell Physiol. 282:C805–C816. 2002. View Article : Google Scholar : PubMed/NCBI

18 

Malinowska DH, Kupert EY, Bahinski A, Sherry AM and Cuppoletti J: Cloning: Functional expression, and characterization of a PKA-activated gastric Cl-channel. Am J Physiol. 268:C191–C200. 1995.PubMed/NCBI

19 

Sherry AM, Malinowska DH, Morris RE, Ciraolo GM and Cuppoletti J: Localization of ClC-2 Cl- channels in rabbit gastric mucosa. Am J Physiol Cell Physiol. 280:C1599–C1606. 2001.PubMed/NCBI

20 

Roman RM, Smith RL, Feranchak AP, Clayton GH, Doctor RB and Fitz JG: ClC-2 chloride channels contribute to HTC cell volume homeostasis. Am J Physiol Gastrointest Liver Physiol. 280:G344–G353. 2001.PubMed/NCBI

21 

Cid LP, Montrose-Rafizadeh C, Smith DI, Guggino WB and Cutting GR: Cloning of a putative human voltage-gated chloride channel (ClC-2) cDNA widely expressed in human tissues. Hum Mol Genet. 4:407–413. 1995. View Article : Google Scholar : PubMed/NCBI

22 

Sherry AM, Stroffekova K, Knapp LM, Kupert EY, Cuppoletti J and Malinowska DH: Characterization of the human pH- and PKA-activated ClC-2G(2 alpha) Cl- channel. Am J Physiol. 273:C384–C393. 1997.PubMed/NCBI

23 

Schwiebert EM, Cid-Soto LP, Stafford D, Carter M, Blaisdell CJ, Zeitlin PL, Guggino WB and Cutting GR: Analysis of ClC-2 channels as an alternative pathway for chloride conduction in cystic fibrosis airway cells. Proc Natl Acad Sci USA. 95:3879–3884. 1998. View Article : Google Scholar : PubMed/NCBI

24 

Blaisdell CJ, Edmonds RD, Wang XT, Guggino S and Zeitlin PL: pH-regulated chloride secretion in fetal lung epithelia. Am J Physiol Lung Cell Mol Physiol. 278:L1248–L1255. 2000.PubMed/NCBI

25 

Cuppoletti J, Tewari KP, Sherry AM, Kupert EY and Malinowska DH: ClC-2 CI- channels in human lung epithelia: Activation by arachidonic acid, amidation, and acid-activated omeprazole. Am J Physiol Cell Physiol. 281:C46–C54. 2001.PubMed/NCBI

26 

Murray CB, Morales MM, Flotte TR, McGrath-Morrow SA, Guggino WB and Zeitlin PL: ClC-2: A developmentally dependent chloride channel expressed in the fetal lung and downregulated after birth. Am J Respir Cell Mol Biol. 12:597–604. 1995. View Article : Google Scholar : PubMed/NCBI

27 

Enz R, Ross BJ and Cutting GR: Expression of the voltage-gated chloride channel ClC-2 in rod bipolar cells of the rat retina. J Neurosci. 19:9841–9847. 1999.PubMed/NCBI

28 

Park K, Arreola J, Begenisich T and Melvin JE: Comparison of voltage-activated CI- channels in rat parotid acinar cells with ClC-2 in a mammalian expression system. J Membr Biol. 163:87–95. 1998. View Article : Google Scholar : PubMed/NCBI

29 

Britton FC, Hatton WJ, Rossow CF, Duan D, Hume JR and Horowitz B: Molecular distribution of volume-regulated chloride channels (ClC-2 and ClC-3) in cardiac tissues. Am J Physiol Heart Circ Physiol. 279:H2225–H2233. 2000.PubMed/NCBI

30 

Sik A, Smith RL and Freund TF: Distribution of chloride channel-2-immunoreactive neuronal and astrocytic processes in the hippocampus. Neuroscience. 101:51–65. 2000. View Article : Google Scholar : PubMed/NCBI

31 

Srinivas SP, Maertens C, Goon LH, Goon L, Satpathy M, Yue BY, Droogmans G and Nilius B: Cell volume response to hyposmotic shock and elevated cAMP in bovine trabecular meshwork cells. Exp Eye Res. 78:15–26. 2004. View Article : Google Scholar : PubMed/NCBI

32 

Comes N, Gasull X, Gual A and Borrás T: Differential expression of the human chloride channel genes in the trabecular meshwork under stress conditions. Exp Eye Res. 80:801–813. 2005. View Article : Google Scholar : PubMed/NCBI

33 

Liang W and Zheng YJ: Effect of chloride channel inhibitor in phagocytic process of human trabecular mesh work cells. Chin J Gerontol. 30:906–908. 2010.

34 

Wang JX, Wang SM and Liu HY: Expression of ClC-2 Chloride channels in rat trabecular meshwork. Chin J Biologicals. 23:274–276. 2010.

35 

Xiong H, Li C, Garami E, Wang Y, Ramjeesingh M, Galley K and Bear CE: ClC-2 activation modulates regulatory volume decrease. J Membr Biol. 167:215–221. 1999. View Article : Google Scholar : PubMed/NCBI

36 

Worrell RT, Butt AG, Cliff WH and Frizzell RA: A volume-sensitive chloride conductance in human colonic cell line T84. Am J Physiol. 256:C1111–C1119. 1989.PubMed/NCBI

37 

Solc CK and Wine JJ: Swelling-induced and depolarization-induced Cl-channels in normal and cystic fibrosis epithelial cells. Am J Physiol. 261:C658–C674. 1991.PubMed/NCBI

38 

Jackson PS and Strange K: Single-channel properties of a volume-sensitive anion conductance. Current activation occurs by abrupt switching of closed channels to an open state. J Gen Physiol. 105:643–660. 1995. View Article : Google Scholar : PubMed/NCBI

39 

Strange K, Emma F and Jackson PS: Cellular and molecular physiology of volume-sensitive anion channels. Am J Physiol. 270:C711–C730. 1996.PubMed/NCBI

40 

Smith RL, Clayton GH, Wilcox CL, Escudero KW and Staley KJ: Differential expression of an inwardly rectifying chloride conductance in rat brain neurons: A potential mechanism for cell-specific modulation of postsynaptic inhibition. J Neurosci. 15:4057–4067. 1995.PubMed/NCBI

41 

Staley K, Smith R, Schaack J, Wilcox C and Jentsch TJ: Alteration of GABAA receptor function following gene transfer of the CLC-2 chloride channel. Neuron. 17:543–551. 1996. View Article : Google Scholar : PubMed/NCBI

42 

Chu S and Zeitlin PL: Alternative mRNA splice variants of the rat ClC-2 chloride channel gene are expressed in lung: Genomic sequence and organization of ClC-2. Nucleic Acids Res. 25:4153–4159. 1997. View Article : Google Scholar : PubMed/NCBI

43 

Chu S, Murray CB, Liu MM and Zeitlin PL: A short CIC-2 mRNA transcript is produced by exon skipping. Nucleic Acids Res. 24:3453–3457. 1996. View Article : Google Scholar : PubMed/NCBI

44 

Chu S, Blaisdell CJ, Liu MZ and Zeitlin PL: Perinatal regulation of the ClC-2 chloride channel in lung is mediated by Sp1 and Sp3. Am J Physiol. 276:L614–L624. 1999.PubMed/NCBI

45 

Dutzler R: The ClC family of chloride channels and transporters. Curr Opin Struct Biol. 16:439–446. 2006. View Article : Google Scholar : PubMed/NCBI

46 

Dutzler R: A structural perspective on ClC channel and transporter function. FEBS Lett. 581:2839–2844. 2007. View Article : Google Scholar : PubMed/NCBI

47 

Ramjeesingh M, Li C, Huan LJ, Garami E, Wang Y and Bear CE: Quaternary structure of the chloride channel ClC-2. Biochemistry. 39:13838–13847. 2000. View Article : Google Scholar : PubMed/NCBI

48 

Varela D, Niemeyer MI, Cid LP and Sepúlveda FV: Effect of an N-terminus deletion on voltage-dependent gating of the ClC-2 chloride channel. J Physiol. 544:363–372. 2002. View Article : Google Scholar : PubMed/NCBI

49 

Stölting G, Fischer M and Fahlke C: ClC-1 and ClC-2 form hetero-dimeric channels with novel protopore functions. Pflugers Arch. 466:2191–2204. 2014. View Article : Google Scholar : PubMed/NCBI

50 

Fritsch J and Edelman A: Modulation of the hyperpolarization-activated Cl- current in human intestinal T84 epithelial cells by phosphorylation. J Physiol. 490:115–128. 1996. View Article : Google Scholar : PubMed/NCBI

51 

Flores CA, Niemeyer MI, Sepúlveda FV and Cid LP: Two splice variants derived from a Drosophila melanogaster candidate ClC gene generate ClC-2-type Cl- channels. Mol Membr Biol. 23:149–156. 2006. View Article : Google Scholar : PubMed/NCBI

52 

Qu C, Liang F, Smythe NM and Schulte BA: Identification of ClC-2 and CIC-K2 chloride channels in cultured rat type IV spiral ligament fibrocytes. J Assoc Res Otolaryngol. 8:205–219. 2007. View Article : Google Scholar : PubMed/NCBI

53 

Fritsch J and Edelman A: Osmosensitivity of the hyperpolarization-activated chloride current in human intestinal T84 cells. Am J Physiol. 272:C778–C786. 1997.PubMed/NCBI

54 

Speakem T, Kajitam H, Smith CP and Brown PD: Inward-rectifying anion channels are expressed in the epithelial cells of choroid plexus isolated from ClC-2 ‘knock-out’ mice. J Physiol. 539:385–390. 2002. View Article : Google Scholar : PubMed/NCBI

55 

Valverde MA, Mintenig GM and Sepúlveda FV: Differential effects of tamoxifen and I- on three distinguishable chloride currents activated in T84 intestinal cells. Pflugers Arch. 425:552–554. 1993. View Article : Google Scholar : PubMed/NCBI

56 

Chesnoy-Marchais D: Hyperpolarization-activated chloride channels in Aplysi a neurons. In Chloride Channels and Carriers in Nerve Muscle and Glial Cells Alvarez-Leefmans. Russell JMFJ: USA: New York Plenum Press; 14. pp. 367–382. 1990

57 

Arreola J, Park K, Melvin JE and Begenisich T: Three distinct chloride channels control anion movements in rat parotid acinar cells. J Physiol. 490:351–362. 1996. View Article : Google Scholar : PubMed/NCBI

58 

Díaz M, Valverde MA, Higgins CF, Rucăreanu C and Sepúlveda FV: Volume-activated chloride channels in HeLa cells are blocked by verapamil and dideoxyforskolin. Pflugers Arch. 422:347–353. 1993. View Article : Google Scholar : PubMed/NCBI

59 

Bond TD, Ambikapathy S, Mohammad S and Valverde MA: Osmosensitive C1- currents and their relevance to regulatory volume decrease in human intestinal T84 cells: Outwardly vs. Inwardly rectifying currents. J Physiol. 511:45–54. 1998. View Article : Google Scholar : PubMed/NCBI

60 

Furukawa T, Horikawa S, Terai T, Ogura T, Katayama Y and Hiraoka M: Molecular cloning and characterization of a novel truncated from (ClC-2 beta) of ClC-2 alpha (ClC-2G) in rabbit heart. FEBS Lett. 375:56–62. 1995. View Article : Google Scholar : PubMed/NCBI

61 

Chamberlin ME and Strange K: Anisosmotic cell volume regulation: A comparative view. Am J Physiol. 257:C159–C173. 1989.PubMed/NCBI

62 

Nehrke K, Arreola J, Nguyen HV, Pilato J, Richardson L, Okunade G, Baggs R, Shull GE and Melvin JE: Loss of hyperpolarization-activated Cl(−) current in salivary acinar cells from Clcn2 knockout mice. J Biol Chem. 277:23604–23611. 2002. View Article : Google Scholar : PubMed/NCBI

63 

Nighot MP, Nighot PK, Ma TY, Malinowska DH, Shull GE, Cuppoletti J and Blikslager AT: Genetic ablation of the ClC-2 Cl- Channel disrupts mouse gastric parietal cell acid secretion. PLoS One. 10:e01381742015. View Article : Google Scholar : PubMed/NCBI

64 

Hori K, Takahashi Y, Horikawa N, Furukawa T, Tsukada K, Takeguchi N and Sakai H: Is the ClC-2 chloride channel involved in the Cl- secretory mechanism of gastric parietal cells? FEBS Lett. 575:105–108. 2004. View Article : Google Scholar : PubMed/NCBI

65 

Liang W, Zheng WX, Sun LX and Zheng YJ: Effect of chloride channel 2 on trabecular meshwork cells under pressure stress condition. Chin J Ophthalmol Otorhinolaryngol. 12:26–29. 2012.

66 

Ugarte G, Delgado R, O'Day PM, Farjah F, Cid LP, Vergara C and Bacigalupo J: Putative ClC-2 chloride channel mediates inward rectification in Drosophila retinal photoreceptors. J Membr Biol. 207:151–160. 2005. View Article : Google Scholar : PubMed/NCBI

67 

Comes N, Abad E, Morales M, Borrás T, Gual A and Gasull X: Identification and functional characterization of ClC-2 chloride channels in trabecular meshwork cells. Exp Eye Res. 83:877–889. 2006. View Article : Google Scholar : PubMed/NCBI

68 

Murray CB, Chu S and Zeitlin PL: Gestational and tissue-specific regulation of C1C-2 chloride channel expression. Am J Physiol. 271:L829–L837. 1996.PubMed/NCBI

69 

Zhou L, Graeff RW, McCray PB Jr, Simonet WS and Whitsett JA: Keratinocyte growth factor stimulates CFTR-independent fluid secretion in the fetal lung in vitro. Am J Physiol. 271:L987–L994. 1996.PubMed/NCBI

70 

Blaisdell CJ, Morales MM, Andrade AC, Bamford P, Wasicko M and Welling P: Inhibition of CLC-2 chloride channel expression interrupts expansion of fetal lung cysts. Am J Physiol Lung Cell Mol Physiol. 286:L420–L426. 2004. View Article : Google Scholar : PubMed/NCBI

71 

Duan D, Ye L, Britton F, Horowitz B and Hume JR: A novel anionic inward rectifier in native cardiac myocytes. Circ Res. 86:E63–E71. 2000. View Article : Google Scholar : PubMed/NCBI

72 

Britton FC, Wang GL, Huang ZM, Ye L, Horowitz B, Hume JR and Duan D: Functional characterization of novel alternatively spliced ClC-2 chloride channel variants in the heart. J Biol Chem. 280:25871–25880. 2005. View Article : Google Scholar : PubMed/NCBI

73 

Huang ZM, Prasad C, Britton FC, Ye LL, Hatton WJ and Duan D: Functional role of CLC-2 chloride inward rectifier channels in cardiac sinoatrial nodal pacemaker cells. Mol Cell Cardiol. 47:121–132. 2009. View Article : Google Scholar

74 

Komukai K, Brette F and Orchard CH: Electrophysiological response of rat atrial myocytes to acidosis. Am J Physiol Heart Circ Physiol. 283:H715–H724. 2002. View Article : Google Scholar : PubMed/NCBI

75 

Komukai K, Brette F, Pascarel C and Orchard CH: Electrophysiological response of rat ventricular myocytes to acidosis. Am J Physiol Heart Circ Physiol. 283:H412–H422. 2002. View Article : Google Scholar : PubMed/NCBI

76 

Földy C, Lee SH, Morgan RJ and Soltesz I: Regulation of fast-spiking basket cell synapses by the chloride channel ClC-2. Nat Neurosci. 13:1047–1049. 2010. View Article : Google Scholar : PubMed/NCBI

77 

Cid LP, Niemeyer MI, Ramírez A and Sepúlveda FV: Splice variants of a ClC-2 chloride channel with differing functional characteristics. Am J Physiol Cell Physiol. 279:C1198–C1210. 2000.PubMed/NCBI

78 

Garcia-Olivares J, Alekov A, Boroumand MR, Begemann B, Hidalgo P and Fahlke C: Gating of human ClC-2 chloride channels and regulation by carboxy-terminal domains. J Physiol. 586:5325–5336. 2008. View Article : Google Scholar : PubMed/NCBI

79 

Eckmann L and Gillin FD: Microbes and microbial toxins: Paradigms for microbial-mucosal interactions I. Pathophysiological aspects of enteric infections with the lumen dwelling protozoan pathogen Giardia lamblia. Am J Physiol Gastrointest Liver Physiol. 280:G1–G6. 2001.PubMed/NCBI

80 

Upcroft P and Upcroft JA: Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin Microbiol Rev. 14:150–164. 2001. View Article : Google Scholar : PubMed/NCBI

81 

Hawrelak J: Giardiasis: Pathophysiology and management. Altern Med Rev. 8:129–142. 2003.PubMed/NCBI

82 

Moreno-Galindo EG, Rodríguez-Elías JC, Ramírez-Herrera MA, Sánchez-Chapula JA and Navarro-Polanco RA: The principal conductance in Giardia lamblia trophozoites possesses functional properties similar to the mammalian ClC-2 current. Pflugers Arch. 466:915–924. 2014. View Article : Google Scholar : PubMed/NCBI

83 

Villaz M, Cinniger JC and Moody WJ: A voltage-gated chloride channel in ascidian embryos modulated by both the cell cycle clock and cell volume. J Physiol. 488:689–699. 1995. View Article : Google Scholar : PubMed/NCBI

84 

Okada Y: Volume expansion-sensing outward-rectifier Cl- channel: Fresh start to the molecular identity and volume sensor. Am J Physiol. 273:C755–C789. 1997.PubMed/NCBI

85 

Tilly BC, van den Berghe N, Tertoolen LG, Edixhoven MJ and de Jonge HR: Protein tyrosine phosphorylation is involved in osmoregulation of ionic conductances. J Biol Chem. 268:19919–19922. 1993.PubMed/NCBI

86 

Sorota S: Tyrosine protein kinase inhibitors prevent activation of cardiac swelling-Induced chloride current. Pflugers Arch. 431:178–185. 1995. View Article : Google Scholar : PubMed/NCBI

87 

Voets T, Manolopoulos V, Eggermont J, Ellory C, Droogmans G and Nilius B: Regulation of a swelling-activated chloride current in bovine endothelium by protein tyrosine phosphorylation and G proteins. J Physiol. 506:341–352. 1998. View Article : Google Scholar : PubMed/NCBI

88 

Lepple-Wienhues A, Szabò I, Laun T, Kaba NK, Gulbins E and Lang F: The tyrosine kinase p56lck mediates activation of swelling-induced chloride channels in lymphocytes. J Cell Biol. 141:281–286. 1998. View Article : Google Scholar : PubMed/NCBI

89 

Santos Ornellas D, Grozovsky R, Goldenberg RC, Carvalho DP, Fong P, Guggino WB and Morales M: Thyroid hormone modulates ClC-2 chloride channel gene expression in rat renal proximal tubules. J Endocrinol. 178:503–511. 2003. View Article : Google Scholar : PubMed/NCBI

90 

Nascimento DS, Reis CU, Goldenberg RC, Ortiga-Carvalho TM, Pazos-Moura CC, Guggino SE, Guggino WB and Morales MM: Estrogen modulates ClC-2 chloride channel gene expression in rat kidney. Pflugers Arch. 446:593–599. 2003. View Article : Google Scholar : PubMed/NCBI

91 

Morales MM, Nascimento DS, Capella MA, Lopes AG and Guggino WB: Arginine vasopressin regulates CFTR and ClC-2 mRNA expression in rat kidney cortex and medulla. Pflugers Arch. 443:202–211. 2001. View Article : Google Scholar : PubMed/NCBI

92 

Moeser AJ, Haskell MM, Shifflett DE, Little D, Schultz BD and Blikslager AT: ClC-2 chloride secretion mediates prostaglandin-induced recovery of barrier function in ischemia-injured porcine ileum. Gastroenterology. 127:802–815. 2004. View Article : Google Scholar : PubMed/NCBI

93 

Moeser AJ, Nighot PK, Engelke KJ, Ueno R and Blikslager AT: Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone. Am J Physiol Gastrointest Liver Physiol. 292:G647–G656. 2007. View Article : Google Scholar : PubMed/NCBI

94 

Cuppoletti J, Malinowska DH, Tewari KP, Li QJ, Sherry AM, Patchen ML and Ueno R: SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol. 287:C1173–C1183. 2004. View Article : Google Scholar : PubMed/NCBI

95 

Bao HF, Liu L, Self J, Duke BJ, Ueno R and Eaton DC: A synthetic prostone activates apical chloride channels in A6 epithelial cells. Am J Physiol Gastrointest Liver Physiol. 295:G234–G251. 2008. View Article : Google Scholar : PubMed/NCBI

96 

Bijvelds MJ, Bot AG, Escher JC and De Jonge HR: Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. Gastroenterology. 137:976–985. 2009. View Article : Google Scholar : PubMed/NCBI

97 

Ao M, Venkatasubramanian J, Boonkaewwan C, Ganesan N, Syed A, Benya RV and Rao MC: Lubiprostone activates Cl- secretion via cAMP signaling and increases membrane CFTR in the human colon carcinoma cell line, T84. Dig Dis Sci. 56:339–351. 2011. View Article : Google Scholar : PubMed/NCBI

98 

Norimatsu Y, Moran AR and MacDonald KD: Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)). Biochem Biophys Res Commun. 426:374–379. 2012. View Article : Google Scholar : PubMed/NCBI

99 

Jin Y, Pridgen TA and Blikslager AT: Pharmaceutical activation or genetic absence of ClC-2 alters tight junctions during experimental colitis. Inflamm Bowel Dis. 21:2747–2757. 2015. View Article : Google Scholar : PubMed/NCBI

100 

Qiu SB, Liang Y and Liu P: Effect of ClC-2 ClC-3 CFTR expression in rats affected with the myocardial ischemia reperfusion injury by Chinese native medicine compound Guangxinkang. Chin J Integrative Med Cardio-/Cerebrovascular Dis. 11:1482–1485. 2013.

101 

Dhani SU, Mohammad-Panah R, Ahmed N, Ackerley C, Ramjeesingh M and Bear CE: Evidence for a functional interaction between the ClC-2 chloride channel and the retrograde motor dynein complex. J Biol Chem. 278:16262–16270. 2003. View Article : Google Scholar : PubMed/NCBI

102 

Furukawa T, Ogura T, Zheng YJ, Tsuchiya H, Nakaya H, Katayama Y and Inagaki N: Phosphorylation and functional regulation of ClC-2 chloride channels expressed in Xenopus oocytes by M cyclin-dependent protein kinase. J Physiol. 540:883–893. 2002. View Article : Google Scholar : PubMed/NCBI

103 

Zheng YJ, Furukawa T, Ogura T, Tajimi K and Inagaki NM: M phase-specific expression and phosphorylation-dependent ubiquitination of the ClC-2 channel. J Biol Chem. 277:32268–32273. 2002. View Article : Google Scholar : PubMed/NCBI

104 

Ahmed N, Ramjeesingh M, Wong S, Varga A, Garami E and Bear CE: Chloride channel activity of ClC-2 is modified by the actin cytoskeleton. Biochem J. 352:789–794. 2000. View Article : Google Scholar : PubMed/NCBI

105 

Hinzpeter A, Lipecka J, Brouillard F, Baudoin-Legros M, Dadlez M, Edelman A and Fritsch J: Association between Hsp90 and the ClC-2 chloride channel upregulates channel function. Am J Physiol Cell Physiol. 290:C45–C56. 2006. View Article : Google Scholar : PubMed/NCBI

106 

Pérez-Rius C, Gaitán-Peñas H, Estévez R and Barrallo-Gimeno A: Identification and characterization of the zebrafish ClC-2 chloride channel orthologs. Pflugers Arch. 467:1769–1781. 2015. View Article : Google Scholar : PubMed/NCBI

107 

Chu S, Blaisdell CJ, Bamford P and Ferro TJ: Interferon-gamma regulates ClC-2 chloride channel in lung epithelial cells. Biochem Biophys Res Commun. 324:31–39. 2004. View Article : Google Scholar : PubMed/NCBI

108 

Palmada M, Dieter M, Boehmer C, Waldegger S and Lang F: Serum and glucocorticoid inducible kinases functionally regulate ClC-2 channels. Biochem Biophys Res Commun. 321:1001–1006. 2004. View Article : Google Scholar : PubMed/NCBI

109 

Hosseinzadeh Z, Bhavsar SK and Lang F: Downregulation of ClC-2 by JAK2. Cell Physiol Biochem. 29:737–742. 2012. View Article : Google Scholar : PubMed/NCBI

110 

Lang F, Föller M, Lang K, Lang P, Ritter M, Vereninov A, Szabo I, Huber SM and Gulbins E: Cell volume regulatory ion channels in cell proliferation and cell death. Methods Enzymol. 428:209–225. 2007. View Article : Google Scholar : PubMed/NCBI

111 

Warsi J, Elvira B, Hosseinzadeh Z, Shumilina E and Lang F: Downregulation of chloride channel ClC-2 by Janus kinase 3. J Membr Biol. 247:387–393. 2014. View Article : Google Scholar : PubMed/NCBI

112 

Klaus F, Laufer J, Czarkowski K, Strutz-Seebohm N, Seebohm G and Lang F: PIKfyve-dependent regulation of the Cl- channel ClC-2. Biochem Biophys Res Commun. 381:407–411. 2009. View Article : Google Scholar : PubMed/NCBI

113 

Park K, Begenisich T and Melvin JE: Protein kinase A activation phosphorylates the rat ClC-2 Cl- channel but does not change activity. J Membr Biol. 182:31–37. 2001. View Article : Google Scholar : PubMed/NCBI

114 

Warsi J, Hosseinzadeh Z, Elvira B, Bissinger R, Shumilina E and Lang F: Regulation of ClC-2 activity by SPAK and OSR1. Kidney Blood Press Res. 39:378–387. 2014. View Article : Google Scholar : PubMed/NCBI

115 

Vij N and Zeitlin PL: Regulation of the ClC-2 lung epithelial chloride channel by glycosylation of SP1. Am J Respir Cell Mol Biol. 34:754–759. 2006. View Article : Google Scholar : PubMed/NCBI

116 

Holmes KW, Hales R, Chu S, Maxwell MJ, Mogayzel PJ Jr and Zeitlin PL: Modulation of Sp1 and Sp3 in lung epithelial cells regulates ClC-2 chloride channel expression. Am J Respir Cell Mol Biol. 29:499–505. 2003. View Article : Google Scholar : PubMed/NCBI

117 

Cuppoletti J, Chakrabarti J, Tewari KP and Malinowska DH: Differentiation between human ClC-2 and CFTR Cl- channels with pharmacological agents. Am J Physiol Cell Physiol. 307:C479–C492. 2014. View Article : Google Scholar : PubMed/NCBI

118 

Thompson CH, Olivetti PR, Fuller MD, Freeman CS, McMaster D, French RJ, Pohl J, Kubanek J and McCarty NA: Isolation and characterization of a high affinity peptide inhibitor of ClC-2 chloride channels. J Biol Chem. 284:26051–26062. 2009. View Article : Google Scholar : PubMed/NCBI

119 

Zhao B, Quan H, Ma T, Tian Y, Cai Q and Li H: 4,4′-Diisothiocyanostilbene-2,2′-disulfonic Acid (DIDS) ameliorates ischemia-hypoxia-induced white matter damage in neonatal rats through inhibition of the voltage-gated chloride channel ClC-2. Int J Mol Sci. 16:10457–10469. 2015. View Article : Google Scholar : PubMed/NCBI

120 

Liang W and Zheng YJ: Effect of interfered ClC-2 gene expression on cell cycle of human trabecular mesh work cells. Chin J Gerontol. 30:1070–1072. 2010.

121 

Thompson CH, Fields DM, Olivetti PR, Fuller MD, Zhang ZR, Kubanek J and McCarty NA: Inhibition of ClC-2 chloride channels by a peptide component or components of scorpion venom. J Membr Biol. 208:65–76. 2005. View Article : Google Scholar : PubMed/NCBI

122 

Baglole CJ, Sigalet DL and Meddings JB: Alpha1-adrenoceptors down-regulate ClC-2 chloride channels in epithelial cells from the acutely denervated jejunum. Eur J Pharmacol. 565:202–206. 2007. View Article : Google Scholar : PubMed/NCBI

123 

Huber SM, Duranton C, Henke G, Van De Sand C, Heussler V, Shumilina E, Sandu CD, Tanneur V, Brand V, Kasinathan RS, et al: Plasmodium induces swelling-activated ClC-2 anion channels in the host erythrocyte. J Biol Chem. 279:41444–41452. 2004. View Article : Google Scholar : PubMed/NCBI

124 

Stölting G, Teodorescu G, Begemann B, Schubert J, Nabbout R, Toliat MR, Sander T, Nürnberg P, Lerche H and Fahlke C: Regulation of ClC-2 gating by intracellular ATP. Pflugers Arch. 465:1423–1437. 2013. View Article : Google Scholar : PubMed/NCBI

125 

Dhani SU, Kim Chiaw P, Huan LJ and Bear CE: ATP depletion inhibits the endocytosis of ClC-2. J Cell Physiol. 214:273–280. 2008. View Article : Google Scholar : PubMed/NCBI

126 

Madison DV, Malenka RC and Nicoll RA: Phorbol esters block a voltage-sensitive chloride current in hippocampal pyramidal cells. Nature. 321:695–697. 1986. View Article : Google Scholar : PubMed/NCBI

127 

Staley K: The role of an inwardly rectifying chloride conductance in postsynaptic inhibition. J Neurophysiol. 72:273–284. 1994.PubMed/NCBI

128 

Rinke I, Artmann J and Stein V: ClC-2 voltage-gated channels constitute part of the background conductance and assist chloride extrusion. J Neurosci. 30:4776–4786. 2010. View Article : Google Scholar : PubMed/NCBI

129 

Schriever AM, Friedrich T, Pusch M and Jentsch TJ: CLC chloride channels in Caenorhabditis elegans. J Biol Chem. 274:34238–34244. 1999. View Article : Google Scholar : PubMed/NCBI

130 

Nehrke K, Begenisich T, Pilato J and Melvin JE: Into ion channel and transporter function. Caenorhabditis elegans ClC-type chloride channels: Novel variants and functional expression. Am J Physiol Cell Physiol. 279:C2052–C2066. 2000.PubMed/NCBI

131 

Denton J, Nehrke K, Rutledge E, Morrison R and Strange K: Alternative splicing of N- and C-termini of a C. Elegans ClC channel alters gating and sensitivity to external Cl- and H+. J Physiol. 555:97–114. 2004. View Article : Google Scholar : PubMed/NCBI

132 

Zhang M, Chung SH, Fang-Yen C, Craig C, Kerr RA, Suzuki H, Samuel AD, Mazur E and Schafer WR: A self-regulating feed-forward circuit controlling C. Elegans egg-laying behavior. Curr Biol. 18:1445–1455. 2008. View Article : Google Scholar : PubMed/NCBI

133 

Desai C and Horvitz HR: Caenorhabditis elegans mutants defective in the functioning of the motor neurons responsible for egg laying. Genetics. 121:703–721. 1989.PubMed/NCBI

134 

Lickteig KM, Duerr JS, Frisby DL, Hall DH, Rand JB and Miller DM III: Regulation of neurotransmitter vesicles by the homeodomain protein UNC-4 and its transcriptional corepressor UNC-37/groucho in Caenorhabditis elegans cholinergic motor neurons. J Neurosci. 21:2001–2014. 2001.PubMed/NCBI

135 

Nathoo AN, Moeller RA, Westlund BA and Hart AC: Identification of neuropeptide-like protein gene families in Caenorhabditis elegans and other species. Proc Natl Acad Sci USA. 98:14000–14005. 2001. View Article : Google Scholar : PubMed/NCBI

136 

Kim K and Li C: Expression and regulation of an FMRFamide-related neuropeptide gene family in Caenorhabditis elegans. J Comp Neuro. 475:540–550. 2004. View Article : Google Scholar

137 

Branicky R, Miyazaki H, Strange K and Schafer WR: The voltage-gated anion channels encoded by clh-3 regulate egg laying in C. Elegans by modulating motor neuron excitability. J Neurosci. 34:764–775. 2014. View Article : Google Scholar : PubMed/NCBI

138 

Niemeyer MI, Cid LP, Yusef YR, Briones R and Sepúlveda FV: Voltage-dependent and -independent titration of specific residues accounts for complex gating of a ClC chloride by extracellular protons. J Physiol. 587:1387–1400. 2009. View Article : Google Scholar : PubMed/NCBI

139 

Sánchez-Rodríguez JE, De Santiago-Castillo JA and Arreola J: Permeant anions contribute to voltage dependence of ClC-2 chloride channel by interacting with the protopore gate. J Physiol. 588:2545–2556. 2010. View Article : Google Scholar : PubMed/NCBI

140 

Hinzpeter A, Fritsch J, Borot F, Trudel S, Vieu DL, Brouillard F, Baudouin-Legros M, Clain J, Edelman A and Ollero M: Membrane cholesterol content modulates ClC-2 gating and sensitivity to oxidative stress. J Biol Chem. 282:2423–2432. 2007. View Article : Google Scholar : PubMed/NCBI

141 

Cornejo I, Niemeyer MI, Zúñiga L, Yusef YR, Sepúlveda FV and Cid LP: Rapid recycling of ClC-2 chloride channels between plasma membrane and endosomes: Role of a tyrosine endocytosis motif in surface retrieval. J Cell Physio. 221:650–657. 2009. View Article : Google Scholar

142 

Light DB, Schwiebert EM, Karlson KH and Stanton BA: Atrial natriuretic peptide inhibits a cation channel in renal inner medullary collecting duct cells. Science. 243:393–395. 1999.

143 

Masilamani S, Kim GH, Mitchell C, Wade JB and Knepper MA: Aldosterone-mediated regulation of ENaC alpha, beta, and gamma subunit proteins in rat kidney. J Clin Invest. 104:R19–R23. 1999. View Article : Google Scholar : PubMed/NCBI

144 

Ewart HS and Klip A: Hormonal regulation of the Na(+)-K(+)-ATPase: Mechanisms underlying rapid and sustained changes in pump activity. Am J Physiol. 269:C295–C311. 1995.PubMed/NCBI

145 

Morales MM, Brucoli HCP, Malnic G and Lopes AG: Role of thyroid hormones in renal tubule acidification. Mol Cell Biochem. 154:17–21. 1996. View Article : Google Scholar : PubMed/NCBI

146 

Katz AI, Emmanouel DS and Lindheimer MD: Thyroid hormone and the kidney. Nephron. 15:223–249. 1975. View Article : Google Scholar : PubMed/NCBI

147 

Shirota T, Shinoda T, Yamada T and Aizawa T: Alteration of renal function in hyperthyroidism: Increased tubular secretion of creatinine and decreased distal tubule delivery of chloride. Metabolism. 41:402–405. 1992. View Article : Google Scholar : PubMed/NCBI

148 

Liu XM, Bai Y and Guo ZS: Study on urinary function and metabolism of water and electrolytes in primary hypothyroidism. Zhonghua Nei Ke Za Zhi. 29:299–302.318. 1990.(In Chinese). PubMed/NCBI

149 

Capasso G, De Tommaso G, Pica A, Anastasio P, Capasso J, Kinne R and De Santo NG: Effects of thyroid hormones on heart and kidney functions. Miner Electrolyte Metab. 25:57–74. 1999. View Article : Google Scholar

150 

Weir RJ, Briggs E, Mack A, Naismith L, Taylor L and Wilson E: Blood pressure in women taking oral contraceptives. Br Med J. 1:533–535. 1974. View Article : Google Scholar : PubMed/NCBI

151 

Meade TW, Haines AP, North WR, Chakrabarti R, Howarth DJ and Stirling Y: Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 microgram or 30 microgram oestrogen. Lancet. 2:948–951. 1977. View Article : Google Scholar : PubMed/NCBI

152 

Seeger H, Armbruster FP, Mueck AO and Lippert TH: The effect of estradiol on urodilatin production in postmenopausal women. Arch Gynecol Obstet. 262:65–68. 1998. View Article : Google Scholar : PubMed/NCBI

153 

Brunette MG and Leclerc M: Effect of estrogen on calcium and sodium transport by the nephron luminal membranes. J Endocrinol. 170:441–450. 2001. View Article : Google Scholar : PubMed/NCBI

154 

Ueno R, Osama H, Habe T, Engelke K and Patchen M: Oral SPI-0211 increases intestinal fluid secretion and chloride concentration without altering serum electrolyte levels (Abstract). Gastroenterology. 126:A–298. 2004.

155 

Johanson JF, Gargano M, Hollan PC, Patchen ML and Ueno R: Phase III efficacy and safety of RU-0211, a novel chloride channel activator, for the treatment of constipation. Gastroenterology. 124:A482003. View Article : Google Scholar

156 

Johanson JF, Gargano MA, Holland PC, Patchen ML and Ueno R: Phase III randomized withdrawal study of RU-0211 a novel chloride channel activator for the treatment of constipation (Abstract). Gastroenterology. 126:A–100. 2004.

157 

Lacy BE and Levy LC: Lubiprostone: A chloride channel activator. J Clin Gastroenterol. 41:345–351. 2007. View Article : Google Scholar : PubMed/NCBI

158 

Shisheva A, Sbrissa D and Lkonomov O: Cloning, characterization, and expression of a novel Zn2+-binding FYVE finger-containing phosphoinositide kinase in insulin-sensitive cells. Mol Cell Biol. 19:623–634. 1999. View Article : Google Scholar : PubMed/NCBI

159 

Morris DL and Rui L: Recent advances in understanding leptin signaling and leptin resistance. Am J Physiol Endocrinol Metab. 297:E1247–E1259. 2009. View Article : Google Scholar : PubMed/NCBI

160 

Brooks AJ and Waters MJ: The growth hormone receptor: Mechanism of activation and clinical implications. Nat Rev Endocrinol. 6:515–525. 2010. View Article : Google Scholar : PubMed/NCBI

161 

Spivak JL: Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation. Ann Intern Med. 152:300–306. 2010. View Article : Google Scholar : PubMed/NCBI

162 

Lopez AF, Hercus TR, Ekert P, Littler DR, Guthridge M, Thomas D, Ramshaw HS, Stomski F, Perugini M, D'Andrea R, et al: Molecular basis of cytokine receptor activation. IUBMB Life. 62:509–518. 2010. View Article : Google Scholar : PubMed/NCBI

163 

Tefferi A, Skoda R and Vardiman JW: Myeloproliferative neoplasms: Contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol. 6:627–637. 2009. View Article : Google Scholar : PubMed/NCBI

164 

Baskin R, Majumder A and Sayeski PP: The recent medicinal chemistry development of Jak2 tyrosine kinase small molecule inhibitors. Curr Med Chem. 17:4551–4558. 2010. View Article : Google Scholar : PubMed/NCBI

165 

Ho K, Valdez F, Garcia R and Tirado CA: JAK2 Translocations in hematological malignancies: Review of the literature. J Assoc Genet Technol. 36:107–109. 2010.PubMed/NCBI

166 

Oh ST and Gotlib J: JAK2 V617F and beyond: Role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Rev Hematol. 3:323–337. 2010. View Article : Google Scholar : PubMed/NCBI

167 

Tefferi A: Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 24:1128–1138. 2010. View Article : Google Scholar : PubMed/NCBI

168 

Pardanani A, Vannucchi AM, Passamonti F, Cervantes F, Barbui T and Tefferi A: JAK inhibitor therapy for myelofibrosis: Critical assessment of value and limitations. Leukemia. 25:218–225. 2011. View Article : Google Scholar : PubMed/NCBI

169 

Santos FP and Verstovsek S: JAK2 inhibitors: What's the true therapeutic potential? Blood Rev. 25:53–63. 2011. View Article : Google Scholar : PubMed/NCBI

170 

Mahfouz RA, Hoteit R, Salem Z, Bazarbachi A, Mugharbel A, Farhat F, Ziyadeh A, Ibrahim A and Taher A: JAK2 V617F gene mutation in the laboratory work-up of myeloproliferative disorders: Experience of a major referral center in Lebanon. Genet Test Mol Biomarkers. 15:263–265. 2011. View Article : Google Scholar : PubMed/NCBI

171 

Gatsios P, Terstegen L, Schliess F, Häussinger D, Kerr IM, Heinrich PC and Graeve L: Activation of the Janus kinase/signal transducer and activator of transcription pathway by osmotic shock. J Biol Chem. 273:22962–22968. 1998. View Article : Google Scholar : PubMed/NCBI

172 

Garnovskaya MN, Mukhin YV, Vlasova TM and Raymond JR: Hypertonicity activates Na+/H+ exchange through Janus kinase 2 and calmodulin. J Biol Chem. 278:16908–16915. 2003. View Article : Google Scholar : PubMed/NCBI

173 

Uckun FM, Vassilev A, Dibirdik I and Tibbles H: Targeting JAK3 tyrosine kinase-linked signal transduction pathways with rationally-designed inhibitors. Anticancer Agents Med Chem. 7:612–623. 2007. View Article : Google Scholar : PubMed/NCBI

174 

de Totero D, Meazza R, Capaia M, Fabbi M, Azzarone B, Balleari E, Gobbi M, Cutrona G, Ferrarini M and Ferrini S: The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways. Blood. 111:517–524. 2008. View Article : Google Scholar : PubMed/NCBI

175 

Fainstein N, Vaknin I, Einstein O, Zisman P, Ben Sasson SZ, Baniyash M and Ben-Hur T: Neural precursor cells inhibit multiple inflammatory signals. Mol Cell Neurosci. 39:335–341. 2008. View Article : Google Scholar : PubMed/NCBI

176 

Nakayama J, Yamamoto M, Hayashi K, Satoh H, Bundo K, Kubo M, Goitsuka R, Farrar MA and Kitamura D: BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3. Blood. 113:1483–1492. 2009. View Article : Google Scholar : PubMed/NCBI

177 

Kim BH, Oh SR, Yin CH, Lee S, Kim EA, Kim MS, Sandoval C, Jayabose S, Bach EA, Lee HK and Baeg GH: MS-1020 is a novel small molecule that selectively inhibits JAK3 activity. Br J Haematol. 148:132–143. 2010. View Article : Google Scholar : PubMed/NCBI

178 

Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M, Goss VL, Lee KA, Eide CA, Wong MJ, et al: Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell. 10:65–75. 2006. View Article : Google Scholar : PubMed/NCBI

179 

Malinge S, Ragu C, Della-Valle V, Pisani D, Constantinescu SN, Perez C, Villeval JL, Reinhardt D, Landman-Parker J, Michaux L, et al: Activating mutations in human acute megakaryoblastic leukemia. Blood. 112:4220–4226. 2008. View Article : Google Scholar : PubMed/NCBI

180 

Haan C, Rolvering C, Raulf F, Kapp M, Drückes P, Thoma G, Behrmann I and Zerwes HG: Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors. Chem Biol. 18:314–323. 2011. View Article : Google Scholar : PubMed/NCBI

181 

Karin M: Too many transcription factors: Positive and negative interactions. New Biol. 2:126–131. 1990.PubMed/NCBI

182 

Latchman DS: Transcription factors: An overview. Int J Biochem Cell Biol. 29:1305–1312. 1997. View Article : Google Scholar : PubMed/NCBI

183 

Nandoskar P, Wang Y, Wei R, Liu Y, Zhao P, Lu M, Huang J, Thomas P, Trousdale MD and Ding C: Changes of chloride channels in the lacrimal glands of a rabbit model of Sjögren syndrome. Cornea. 31:273–279. 2012. View Article : Google Scholar : PubMed/NCBI

184 

Ding C, Parsa L, Nandoskar P, Zhao P, Wu K and Wang Y: Duct system of the rabbit lacrimal gland: Structural characteristics and role in lacrimal secretion. Invest Ophthalmol Vis Sci. 51:2960–2967. 2010. View Article : Google Scholar : PubMed/NCBI

185 

Ouyang WB: Correlation between ClC-2 chloride channel and age related cataract Master's thesis. Dalian Med Univ Dalian. 2013.

186 

Li HB, Han DM, Zhong B, Fan EZ and Liu ZY: Expressions of chloride channel ClC-2 and ClC-3 in human nasal polyps. J Clin Otorhinolaryngol. 17:266–277. 2003.

187 

Edwards MM, de Evsikova Marín C, Collin GB, Gifford E, Wu J, Hicks WL, Whiting C, Varvel NH, Maphis N, Lamb BT, et al: Photoreceptor degeneration, azoospermia, leukoencephalopathy, and abnormal RPE cellfunction in mice expressing an early stop mutation in CLCN2. Invest Ophthalmol Vis Sci. 51:3264–3272. 2010. View Article : Google Scholar : PubMed/NCBI

188 

Xu ZN, Zheng XY, Zhao W, Xin H and Han ZG: Expression and significance of chloride channel ClC-2 in nonsmall-cell lung cancer. Chin J Lab Diagn. 16:60–62. 2012.

189 

Diener M, Bertog M, Fromm M and Scharrer E: Segmental heterogeneity of swelling-induced Cl- transport in rat small intestine. Pflugers Arch. 432:293–300. 1996. View Article : Google Scholar : PubMed/NCBI

190 

Joo NS, Clarke LL, Han BH, Forte LR and Kim HD: Cloning of ClC-2 chloride channel from murine duodenum and its presence in CFTR knockout mice. Biochim Biophys Acta. 1446:431–437. 1999. View Article : Google Scholar : PubMed/NCBI

191 

Catalán MA, Flores CA, González-Begne M, Zhang Y, Sepúlveda FV and Melvin JE: Severe defects in absorptive ion transport in distal colons of mice that lack ClC-2 channels. Gastroenterology. 142:346–354. 2012. View Article : Google Scholar : PubMed/NCBI

192 

Lacy BE and Chey WD: Lubiprostone: Chronic constipation and irritable bowel syndrome with constipation. Expert Opin Pharmacother. 10:143–152. 2009. View Article : Google Scholar : PubMed/NCBI

193 

Crowell MD, Harris LA, DiBaise JK and Olden KW: Activation of type-2 chloride channels: A novel therapeutic target for the treatment of chronic constipation. Curr Opin Invest Drugs. 8:66–70. 2007.

194 

Chen ZY, Wang YG, Yang P, Huang WG, Zhou YS and Feng XS: Relationship between ClC-2 and intestinal mucosal barrier in rats with obstructive jaundice. World Chin J Digestology. 19:2829–2834. 2011.

195 

Jiang B, Hattori N, Liu B, Kitagawa K and Inagaki C: Expression of swelling- and/or pH-regulated chloride channels (ClC-2,3,4 and 5) in human leukemic and normal immune cells. Life Sci. 70:1383–1394. 2002. View Article : Google Scholar : PubMed/NCBI

196 

Blaisdell CJ, Howard TD, Stern A, Bamford P, Bleecker ER and Stine OC: CLC-2 single nucleotide polymorphisms (SNPs) as potential modifiers of cystic fibrosis disease severity. BMC Med Genet. 5:262004. View Article : Google Scholar : PubMed/NCBI

197 

Cuppoletti J, Tewari KP, Sherry AM, Kupert EY and Malinowska DH: Human ClC-2- chloride channels can be activated Potential for therapy in cystic fibrosis. Faseb J. 15:A8472001.

198 

Zdebik AA, Cuffe JE, Bertog M, Korbmacher C and Jentsch TJ: Additional disruption of the ClC-2 Cl(−) channel does not exacerbate the cystic fibrosis phenotype of cystic fibrosis transmembrane conductance regulator mouse models. J Biol Chem. 279:22276–22283. 2004. View Article : Google Scholar : PubMed/NCBI

199 

Jeworutzki E, López-Hernández T, Capdevila-Nortes X, Sirisi S, Bengtsson L, Montolio M, Zifarelli G, Arnedo T, Müller CS, Schulte U, et al: GlialCAM, a protein defective in a leukodystrophy, serves as a ClC-2 Cl(−) channel auxiliary subunit. Neuron. 73:951–961. 2012. View Article : Google Scholar : PubMed/NCBI

200 

Jeworutzki E, Lagostena L, Elorza-Vidal X, López-Hernández T, Estévez R and Pusch M: GlialCAM a CLC-2 Cl(−) channel subunit activates the slow gate of CLC chloride channels. Biophys J. 107:1105–1116. 2014. View Article : Google Scholar : PubMed/NCBI

201 

Hoegg-Beiler MB, Sirisi S, Orozco IJ, Ferrer I, Hohensee S, Auberson M, Gödde K, Vilches C, de Heredia ML, Nunes V, et al: Disrupting MLC1 and GlialCAM and ClC-2 interactions in leukodystrophy entails glial chloride channel dysfunction. Nat Commun. 5:34752014. View Article : Google Scholar : PubMed/NCBI

202 

Scheper GC, van Berkel CG, Leisle L, de Groot KE, Errami A, Jentsch TJ and Van der Knaap MS: Analysis of CLCN2 as candidate gene for megalencephalic leukoencephalopathy with subcortical cysts. Genet Test Mol Biomarkers. 14:255–257. 2010. View Article : Google Scholar : PubMed/NCBI

203 

Gulácsi A, Lee CR, Sik A, Viitanen T, Kaila K, Tepper JM and Freund TF: Cell type-specific differences in chloride-regulatory mechanisms and GABA(A) receptor-mediated inhibition in rat substantia nigra. J Neurosci. 23:8237–8246. 2003.PubMed/NCBI

204 

Ferroni S, Marchini C, Nobile M and Rapisarda C: Characterization of an inwardly rectifying chloride conductance expressed by cultured rat cortical astrocytes. Glia. 21:217–227. 1997. View Article : Google Scholar : PubMed/NCBI

205 

Nobile M, Pusch M, Rapisarda C and Ferroni S: Single-channel analysis of a ClC-2-like chloride conductance in cultured rat cortical astrocytes. FEBS Lett. 479:10–14. 2000. View Article : Google Scholar : PubMed/NCBI

206 

Makara JK, Petheö GL, Tóth A and Spät A: pH-sensitive inwardly rectifying chloride current in cultured rat cortical astrocytes. Glia. 34:52–58. 2001. View Article : Google Scholar : PubMed/NCBI

207 

Makara JK, Rappert A, Matthias K, Steinhäuser C, Spät A and Kettenmann H: Astrocytes from mouse brain slices express ClC-2-mediated Cl- currents regulated during development and after injury. Mol Cell Neurosci. 23:521–530. 2003. View Article : Google Scholar : PubMed/NCBI

208 

Niemeyer MI, Yusef YR, Cornejo I, Flores CA, Sepúlveda FV and Cid LP: Functional evaluation of human ClC-2 chloride channel mutations associated with idiopathic generalized epilepsies. Physiol Genomics. 19:74–83. 2004. View Article : Google Scholar : PubMed/NCBI

209 

Sander T, Schulz H, Saar K, Gennaro E, Riggio MC, Bianchi A, Zara F, Luna D, Bulteau C, Kaminska A, et al: Genome search for susceptibility loci of common idiopathic generalised epilepsies. Hum Mol Genet. 9:1465–1472. 2000. View Article : Google Scholar : PubMed/NCBI

210 

Haug K, Warnstedt M, Alekov AK, Sander T, Ramirez A, Poser B, Maljevic S, Hebeisen S, Kubisch C, Rebstock J, et al: Mutations in CLCN2 encoding a voltage-gated chloride channel are associated with idiopathic generalized epilepsies. Nat Genet. 33:527–532. 2003. View Article : Google Scholar : PubMed/NCBI

211 

Blanz J, Schweizer M, Auberson M, Maier H, Muenscher A, Hübner CA and Jentsch TJ: Leukoencephalopathy upon disruption of the chloride channel ClC-2. J Neurosci. 27:6581–6589. 2007. View Article : Google Scholar : PubMed/NCBI

212 

Ge YX, Liu Y, Tang HY, Liu XG and Wang X: ClC-2 contributes to tonic inhibition mediated by α5 subunit-containing GABA(A) receptor in experimental temporal lobe epilepsy. Neuroscience. 186:120–127. 2011. View Article : Google Scholar : PubMed/NCBI

213 

Pan F, Guo R, Cheng W, Chai L, Wang W, Cao C and Li S: High glucose inhibits ClC-2 chloride channels and attenuates cell migration of rat keratinocytes. Drug Des Devel Ther. 9:4779–4791. 2015.PubMed/NCBI

214 

Borchers AT, Naguwa SM, Keen CL and Gershwin ME: Immunopathogenesis of Sjögren's syndrome. Clin Rev Allergy Immunol. 25:89–104. 2003. View Article : Google Scholar : PubMed/NCBI

215 

Nocturne G and Mariette X: Advances in understanding the pathogenesis of primary Sjogren's syndrome. Nat Rev Rheumatol. 9:544–556. 2013. View Article : Google Scholar : PubMed/NCBI

216 

Guo Z, Song D, Azzarolo AM, Schechter JE, Warren DW, Wood RL, Mircheff AK and Kaslow HR: Autologous lacrimal lymphoid mixed-cell reactions induce dacryoadenitis in rabbits. Exp Eye Res. 71:23–31. 2000. View Article : Google Scholar : PubMed/NCBI

217 

Zhu Z, Stevenson D, Schechter JE, Mircheff AK, Atkinson R and Trousdale MD: Lacrimal histopathology and ocular surface disease in a rabbit model of autoimmune dacryoadenitis. Cornea. 22:25–32. 2003. View Article : Google Scholar : PubMed/NCBI

218 

Thomas PB, Zhu Z, Selvam S, Samant DM, Stevenson D, Mircheff AK, Schechter JE, Song SW and Trousdale MD: Autoimmune dacryoadenitis and keratoconjunctivitis induced in rabbits by subcutaneous injection of autologous lymphocytes activated ex vivo against lacrimal antigens. J Autoimmun. 31:116–122. 2008. View Article : Google Scholar : PubMed/NCBI

219 

Chan HC, Ruan YC, He Q, Chen MH, Chen H, Xu WM, Chen WY, Xie C, Zhang XH and Zhou Z: The cystic fibrosis transmembrane conductance regulator in reproductive health and disease. J Physiol. 587:2187–2195. 2009. View Article : Google Scholar : PubMed/NCBI

220 

Yeung CH, Barfield JP and Cooper TG: Chloride channels in physiological volume regulation of human spermatozoa. Biol Reprod. 73:1057–1063. 2005. View Article : Google Scholar : PubMed/NCBI

221 

Anderson MP, Sheppard DN, Berger HA and Welsh M: Chloride channels in the apical membrane of normal and cystic fibrosis airway and intestinal epithelia. Am J Physiol. 263:L1–L14. 1992.PubMed/NCBI

222 

O'Sullivan BP and Freedman SD: Cystic fibrosis. Lancet. 373:1891–1904. 2009. View Article : Google Scholar : PubMed/NCBI

223 

Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, et al: Identification of the cystic fibrosis gene: Cloning and characterization of complementary. Science. 245:1066–1073. 1989. View Article : Google Scholar : PubMed/NCBI

224 

Van der Knaap MS, Barth PG, Stroink H, van Nieuwenhuizen O, Arts WF, Hoogenraa F and Valk J: Leukoencephalopathy with swelling and a discrepantly mild clinical course in eight children. Ann Neurol. 37:324–334. 1995. View Article : Google Scholar : PubMed/NCBI

225 

Hauser WA, Annegers JF and Rocca WA: Descriptive epidemiology of epilepsy: Contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc. 71:576–586. 1996. View Article : Google Scholar : PubMed/NCBI

226 

Ji ZY: Research progress of chloride channel ClC- 2. J Kunm Med Univ. 30:68–72. 2009.

Related Articles

Journal Cover

July-2017
Volume 16 Issue 1

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang H, Xu M, Kong Q, Sun P, Yan F, Tian W and Wang X: Research and progress on ClC‑2 (Review). Mol Med Rep 16: 11-22, 2017
APA
Wang, H., Xu, M., Kong, Q., Sun, P., Yan, F., Tian, W., & Wang, X. (2017). Research and progress on ClC‑2 (Review). Molecular Medicine Reports, 16, 11-22. https://doi.org/10.3892/mmr.2017.6600
MLA
Wang, H., Xu, M., Kong, Q., Sun, P., Yan, F., Tian, W., Wang, X."Research and progress on ClC‑2 (Review)". Molecular Medicine Reports 16.1 (2017): 11-22.
Chicago
Wang, H., Xu, M., Kong, Q., Sun, P., Yan, F., Tian, W., Wang, X."Research and progress on ClC‑2 (Review)". Molecular Medicine Reports 16, no. 1 (2017): 11-22. https://doi.org/10.3892/mmr.2017.6600